ATE269978T1 - Verfahren zur bestimmung der prognose eines patienten mit einer neurologischen krankheit - Google Patents
Verfahren zur bestimmung der prognose eines patienten mit einer neurologischen krankheitInfo
- Publication number
- ATE269978T1 ATE269978T1 AT97952129T AT97952129T ATE269978T1 AT E269978 T1 ATE269978 T1 AT E269978T1 AT 97952129 T AT97952129 T AT 97952129T AT 97952129 T AT97952129 T AT 97952129T AT E269978 T1 ATE269978 T1 AT E269978T1
- Authority
- AT
- Austria
- Prior art keywords
- patient
- prognosis
- determining
- neurological disease
- disease
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title abstract 4
- 208000025966 Neurological disease Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 238000004393 prognosis Methods 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 3
- 101150037123 APOE gene Proteins 0.000 abstract 1
- 108700028369 Alleles Proteins 0.000 abstract 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/766,975 US6022683A (en) | 1996-12-16 | 1996-12-16 | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
| PCT/IB1997/001641 WO1998027226A2 (en) | 1996-12-16 | 1997-12-16 | Method for determining the prognosis of a patient with a neurological disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE269978T1 true ATE269978T1 (de) | 2004-07-15 |
Family
ID=25078098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97952129T ATE269978T1 (de) | 1996-12-16 | 1997-12-16 | Verfahren zur bestimmung der prognose eines patienten mit einer neurologischen krankheit |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6022683A (enExample) |
| EP (2) | EP0948647B1 (enExample) |
| JP (4) | JP2001524809A (enExample) |
| AT (1) | ATE269978T1 (enExample) |
| AU (2) | AU5571798A (enExample) |
| CA (2) | CA2275404C (enExample) |
| DE (2) | DE69729473T2 (enExample) |
| WO (2) | WO1998027226A2 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6022683A (en) * | 1996-12-16 | 2000-02-08 | Nova Molecular Inc. | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
| US6441149B1 (en) | 1998-06-15 | 2002-08-27 | Mitokor | Diagnostic method based on quantification of extramitochondrial DNA |
| US6218117B1 (en) | 1998-06-15 | 2001-04-17 | Mitokor | Compositions and methods for identifying agents that quantitatively alter detectable extramitochondrial DNA:mitochondrial DNA ratios |
| US6489095B2 (en) | 1998-06-15 | 2002-12-03 | Mitokor | Diagnostic method based on quantification of extramitochondrial DNA |
| EP1088104B1 (en) * | 1998-06-16 | 2006-02-08 | Nova Molecular, Inc. | Methods for treating a neurological disease by determining bche genotype |
| WO2000020634A1 (en) | 1998-10-01 | 2000-04-13 | Nova Molecular, Inc. | Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele |
| WO2000070340A2 (en) * | 1999-05-14 | 2000-11-23 | Karolinska Innovations Ab | Materials and methods relating to disease diagnosis |
| DE1233365T1 (de) * | 1999-06-25 | 2003-03-20 | Genaissance Pharmaceuticals Inc., New Haven | Verfahren zur herstellung und verwendung von Haplotype Daten |
| US7058517B1 (en) | 1999-06-25 | 2006-06-06 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
| US6692916B2 (en) * | 1999-06-28 | 2004-02-17 | Source Precision Medicine, Inc. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
| US6960439B2 (en) * | 1999-06-28 | 2005-11-01 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
| US6573049B1 (en) | 1999-07-26 | 2003-06-03 | Nuvelo, Inc. | Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease |
| US6896881B1 (en) * | 1999-09-24 | 2005-05-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
| AU2001240820A1 (en) * | 2000-03-15 | 2001-09-24 | Oxford Glycosciences (Uk) Ltd. | Proteins, genes and their use for diagnosis and treatment of vascular dementia |
| US20080009467A1 (en) * | 2000-05-01 | 2008-01-10 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism |
| US20070179197A1 (en) * | 2000-05-01 | 2007-08-02 | Accera, Inc. | Compositions and methods for improving or preserving brain function |
| US8124589B2 (en) | 2000-05-01 | 2012-02-28 | Accera, Inc. | Use of ketogenic compounds for treatment of age-associated memory impairment |
| US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| WO2001082928A1 (en) * | 2000-05-01 | 2001-11-08 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism |
| US6931326B1 (en) | 2000-06-26 | 2005-08-16 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
| US6399310B1 (en) | 2001-02-12 | 2002-06-04 | Akzo Nobel N.V. | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
| WO2002064735A2 (en) * | 2001-02-12 | 2002-08-22 | Akzo Nobel N.V. | Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 |
| US20030105082A1 (en) * | 2001-12-03 | 2003-06-05 | Murphy Greer Marechal | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
| GB0106051D0 (en) * | 2001-03-12 | 2001-05-02 | Isis Innovation | Diagnostic screens for alzheimer's disease |
| US20030104453A1 (en) * | 2001-11-06 | 2003-06-05 | David Pickar | System for pharmacogenetics of adverse drug events |
| EP1451340B1 (en) | 2001-11-09 | 2014-01-08 | Life Technologies Corporation | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
| US20030224446A1 (en) * | 2001-12-20 | 2003-12-04 | Harry G. Jean | Method of predicting cytokine response to tissue injury |
| US20040267458A1 (en) * | 2001-12-21 | 2004-12-30 | Judson Richard S. | Methods for obtaining and using haplotype data |
| WO2003069431A2 (en) * | 2002-02-14 | 2003-08-21 | Medavante, Inc. | System and method for facilitating candidate and subject participation in clinical trial studies |
| US7432355B2 (en) * | 2002-08-09 | 2008-10-07 | The J. David Gladstone Institutes | Apolipoprotein E stable folding intermediate and methods of use thereof |
| US8688385B2 (en) | 2003-02-20 | 2014-04-01 | Mayo Foundation For Medical Education And Research | Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype |
| EP1636592B1 (en) * | 2003-06-19 | 2012-12-19 | Merck Serono SA | Use of prion conversion modulating agents |
| US20050038692A1 (en) * | 2003-08-14 | 2005-02-17 | Kane John Michael | System and method for facilitating centralized candidate selection and monitoring subject participation in clinical trial studies |
| EP1706837A2 (en) * | 2004-01-16 | 2006-10-04 | Disease Management Services, Plc | Disease management system |
| KR20070033032A (ko) | 2004-07-16 | 2007-03-23 | 프로테오시스 악티엔게젤샤프트 | 세포보호제로서 ｐａｒｐ 및 ｓｉｒ 조절 활성을 갖는무스카린 길항제 |
| US20060252775A1 (en) * | 2005-05-03 | 2006-11-09 | Henderson Samuel T | Methods for reducing levels of disease associated proteins |
| EP2468273A3 (en) * | 2005-06-20 | 2012-07-11 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
| CA2630604C (en) * | 2005-11-29 | 2016-01-19 | Children's Hospital Medical Center | Optimization and individualization of medication selection and dosing |
| US20080126118A1 (en) * | 2006-11-24 | 2008-05-29 | General Electric Company, A New York Corporation | Systems, methods and apparatus for a network application framework system |
| TWI362012B (en) * | 2007-07-23 | 2012-04-11 | System of providing hygienic education information and method thereof | |
| ES2556534T3 (es) | 2007-07-31 | 2016-01-18 | Accera, Inc. | Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida |
| US20090198504A1 (en) * | 2008-02-05 | 2009-08-06 | Medavante, Inc. | Rater resource allocation systems and methods |
| US9125881B2 (en) * | 2008-07-03 | 2015-09-08 | Accera, Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
| US8105809B2 (en) * | 2008-07-03 | 2012-01-31 | Accera, Inc. | Enzymatic synthesis of acetoacetate esters and derivatives |
| EP2387405A2 (en) | 2009-01-13 | 2011-11-23 | ProteoSys AG | Pirenzepine as an agent in cancer treatment |
| EP2360280A1 (en) * | 2010-02-24 | 2011-08-24 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Genetic marker for the diagnosis of dementia with Lewy bodies |
| US20120078521A1 (en) * | 2010-09-27 | 2012-03-29 | General Electric Company | Apparatus, system and methods for assessing drug efficacy using holistic analysis and visualization of pharmacological data |
| US20130080182A1 (en) * | 2011-09-26 | 2013-03-28 | Athleticode Inc. | Methods For Using DNA Testing To Screen For Genotypes Relevant To Athleticism, Health And Risk Of Injury |
| RU2467680C1 (ru) * | 2011-10-04 | 2012-11-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации | Способ прогнозирования эффективности лечения больных ишемическим инсультом |
| US10665328B2 (en) | 2014-06-30 | 2020-05-26 | QIAGEN Redwood City, Inc. | Methods and systems for interpretation and reporting of sequence-based genetic tests |
| US10658073B2 (en) | 2014-08-15 | 2020-05-19 | QIAGEN Redwood City, Inc. | Methods and systems for interpretation and reporting of sequence-based genetic tests using pooled allele statistics |
| EP3628315A1 (en) | 2018-09-28 | 2020-04-01 | Université de Caen Normandie | Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases |
| WO2020091375A2 (ko) * | 2018-10-29 | 2020-05-07 | 고려대학교 산학협력단 | 항우울제 추천 방법 및 시스템 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100279898B1 (ko) * | 1992-10-13 | 2001-04-02 | 로버트 엘. 타버 | 알쯔하이머 질환의 검출방법 |
| CA2111503A1 (en) * | 1993-12-15 | 1995-06-16 | Mcgill University | Apolipoprotein e polymorphism and alzheimer's disease |
| FR2716894B1 (fr) * | 1994-03-07 | 1996-05-24 | Pasteur Institut | Marqueurs génétiques utilisés conjointement pour le diagnostic de la maladie d'Alzheimer, méthode et kit de diagnostic. |
| GB9408465D0 (en) * | 1994-04-27 | 1994-06-22 | Univ Mcgill | Apolipoprotein e polymorphism & treatment of alzheimer's disease |
| GB9415073D0 (en) * | 1994-06-27 | 1994-09-14 | Smithkline Beecham Plc | Novel method |
| GB9414624D0 (en) * | 1994-07-20 | 1994-09-07 | Smithkline Beecham Plc | Novel method |
| US6022683A (en) * | 1996-12-16 | 2000-02-08 | Nova Molecular Inc. | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
-
1996
- 1996-12-16 US US08/766,975 patent/US6022683A/en not_active Expired - Lifetime
-
1997
- 1997-12-16 WO PCT/IB1997/001641 patent/WO1998027226A2/en not_active Ceased
- 1997-12-16 AT AT97952129T patent/ATE269978T1/de not_active IP Right Cessation
- 1997-12-16 CA CA2275404A patent/CA2275404C/en not_active Expired - Fee Related
- 1997-12-16 EP EP97952129A patent/EP0948647B1/en not_active Expired - Lifetime
- 1997-12-16 DE DE69729473T patent/DE69729473T2/de not_active Expired - Lifetime
- 1997-12-16 DE DE69729654T patent/DE69729654T2/de not_active Expired - Lifetime
- 1997-12-16 AU AU55717/98A patent/AU5571798A/en not_active Withdrawn
- 1997-12-16 CA CA002275504A patent/CA2275504C/en not_active Expired - Fee Related
- 1997-12-16 WO PCT/IB1997/001648 patent/WO1998027227A2/en not_active Ceased
- 1997-12-16 JP JP52750798A patent/JP2001524809A/ja not_active Withdrawn
- 1997-12-16 EP EP97953011A patent/EP0946753B1/en not_active Expired - Lifetime
- 1997-12-16 AU AU56757/98A patent/AU745073B2/en not_active Ceased
-
2000
- 2000-02-08 US US09/500,162 patent/US7001736B1/en not_active Expired - Fee Related
-
2009
- 2009-05-07 JP JP2009113073A patent/JP5202429B2/ja not_active Expired - Fee Related
-
2012
- 2012-05-23 JP JP2012117411A patent/JP2012152229A/ja active Pending
- 2012-12-17 JP JP2012274378A patent/JP2013059347A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998027227A3 (en) | 1998-08-27 |
| CA2275504C (en) | 2009-09-22 |
| AU5571798A (en) | 1998-07-15 |
| EP0948647B1 (en) | 2004-06-23 |
| WO1998027226A2 (en) | 1998-06-25 |
| AU745073B2 (en) | 2002-03-14 |
| JP2013059347A (ja) | 2013-04-04 |
| EP0948647A1 (en) | 1999-10-13 |
| DE69729654D1 (de) | 2004-07-29 |
| WO1998027226A3 (en) | 1998-08-20 |
| CA2275404C (en) | 2011-02-08 |
| AU5675798A (en) | 1998-07-15 |
| DE69729654T2 (de) | 2005-07-21 |
| CA2275404A1 (en) | 1998-06-25 |
| WO1998027227A2 (en) | 1998-06-25 |
| JP2009213482A (ja) | 2009-09-24 |
| JP2012152229A (ja) | 2012-08-16 |
| US6022683A (en) | 2000-02-08 |
| CA2275504A1 (en) | 1998-06-25 |
| US7001736B1 (en) | 2006-02-21 |
| DE69729473T2 (de) | 2005-06-09 |
| EP0946753A2 (en) | 1999-10-06 |
| JP5202429B2 (ja) | 2013-06-05 |
| EP0946753B1 (en) | 2004-06-09 |
| DE69729473D1 (de) | 2004-07-15 |
| JP2001524809A (ja) | 2001-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE269978T1 (de) | Verfahren zur bestimmung der prognose eines patienten mit einer neurologischen krankheit | |
| DE69531743D1 (de) | System und verfahren zur diagnose von krankheiten an lebendem gewebe | |
| DE69942614D1 (de) | Vorrichtung zur diagnose und therapie von elektrophysiologischen krankheiten | |
| CA2241111A1 (en) | Process for the microbial production of amino acids by boosted activity of export carriers | |
| WO1995029257A3 (en) | Apolipoprotein e polymorphism and treatment of alzheimer's disease | |
| EP1187844A4 (en) | POLYMORPHISM OF HUMAN CARBAMYLPHOSPHATE SYNTHETASE I AND RELATED DIAGNOSTIC AND THERAPEUTIC METHODS | |
| DE69510810D1 (de) | Lamanin-ketten: diagnostische und therapeutische verwendung | |
| KR920700667A (ko) | 세포간 점착분자 및 그의 결합리간드의 천식치료에의 이용 | |
| DE69929787D1 (de) | Verfahren zur behandlung von neurologischen erkrankungen mit hilfe der bestimmung des bche genotyps | |
| ATE122467T1 (de) | Verfahren zur detektion von knochen- und anderen bindegewebeerkrankungen bei menschen und tieren. | |
| EP1109929A4 (en) | METHODS OF DIAGNOSING RENAL SALT LOSS SYNDROME AND ALZHEIMER'S DISEASE AND METHODS OF TREATMENT THEREOF | |
| ATE126599T1 (de) | Verfahren zur bestimmung von anti-rns- antikörpern. | |
| ATE215830T1 (de) | Verfahren zur detektion und behandlung von individuen mit abnormal hla-a2/tyrosinase- peptidantigenen exprimierenden zellen | |
| BR9809678A (pt) | Derivados de triptolìdeo úteis no tratamento de doenças autoimunes | |
| DE69903278D1 (de) | Verfahren zur Diagnose oder zur Prognose von Alzheimer Krankheit: therapeutische Zusammensetzung zur Verhinderung oder zur Behandlung von Alzheimer Krankheit | |
| AU5153398A (en) | Diagnostic method for the detection of alzheimer's disease in living patients | |
| DE69505376D1 (de) | Alpha b crystallin zur verwendung in diagnose und therapie von autoimmunkrankheiten, besonders multipler skerose | |
| DE69636367D1 (de) | T-pa polymorphismus und dessen verwendung zur risikodiagnose von thrombus assoziierten krankheiten | |
| EP0870036A4 (en) | SYNTHETIC MAMMAL ALPHA-N-AECTYL GLUCOSAMINIDASE AND ENCODING GENETIC SEQUENCES THEREFOR | |
| ATE293994T1 (de) | Multivalente rekombinante antikörper zur behandlung von hrv infektionen | |
| DE69028023D1 (de) | Verfahren zur Bestimmung des Cholesterins, zum Nachweis von Gefässkrankheiten und zur Anhebung des Anteils an HDL-Cholesterin | |
| AU2003208857A8 (en) | Diagnostic and therapeutic use of caps | |
| DE69013139D1 (de) | Mittel zur Vorbeugung, Diagnose und Therapie von rheumatischen, autoimmunen, Haut- und Bindegewebekrankheiten von unbekannter Aetiologie und Verfahren zu seiner Herstellung und Verwendung. | |
| EP1432736A4 (en) | METHODS FOR DIAGNOSING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH C $ G PROTEIN KINASE (L) | |
| ATE365175T1 (de) | Diagnostische und therapeutische verwendung von humanen maguinproteinen und nukleinsäuren bei neurodegenerativen krankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |